A Study of the Effect of Lenalidamide on Complex Regional Pain Syndrome Type 1

Completed · Phase 3

Conditions studied: Complex Regional Pain Syndrome, Type 1

In brief

The purpose of this study is to determine if lenalidomide is a safe and effective treatment for complex regional pain syndrome type 1 (CRPS).

Key facts

Study ID

NCT00166452

Run by

Mayo Clinic

People needed

7

Starts

2005-07-01

Expected to finish

2009-02-01

Last updated by the study team

2011-03-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age > or = to 18 years
• Signed consent form
• A diagnosis of CRPS type I for at least one-year duration with unilateral involvement of a distal limb
• CRPS pain intensity score at least 4 on an 11-point PI-NRS
• Measurable sural, median sensory, median motor and peroneal motor nerve conductions
• Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of starting the study drug. They must agree to use adequate contraceptive methods not including steroid-based contraceptives. They must also agree to have pregnancy tests every 4 weeks while on the study drug.

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.